Patients with wild-type RAS WT (KRAS exons 2, 3, and 4 and NRAS exons 2, 3, 4) unresectable mCRC who were treated with cetuximab-based chemotherapy as the first-line therapy between January 2013 and December 2018 at the Zhejiang Cancer Hospital (Hangzhou, China) were retrospectively investigated. Chemotherapy regimens were not restricted. The study was approved by the Ethics Committee and Institutional Review Board of Zhejiang Cancer Hospital and was conducted in compliance with the Helsinki Declaration. The main objective of the study should be progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), and disease control rate (DCR).
The follow-up period was defined as the time from diagnosis to the last observation or death. Progression-free survival was defined as the time between the date of the time from randomization until patient’s tumor progression and death. The log-rank test was used to estimate and compare survival. IBM SPSS Statistics 22 statistical software was used to statistically analyze the data.
The follow-up period was defined as the time from diagnosis to the last observation or death. Progression-free survival was defined as the time between the date of the time from randomization until patient’s tumor progression and death. The log-rank test was used to estimate and compare survival. IBM SPSS Statistics 22 statistical software was used to statistically analyze the data.